☆ 4.6 Article

Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia

Tim Grob et al.

Summary: The study demonstrates that the next-generation sequencing-based detection of FLT3-ITD MRD predicts the risk of relapse and overall survival in patients with AML. The prognostic value of FLT3-ITD MRD exceeds that of other established clinical and molecular prognostic factors, highlighting its significance as a clinically relevant biomarker for dynamic disease risk assessment in AML.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Acute Myeloid Leukemia, Version 3.2023

Daniel A. Pollyea et al.

Summary: Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts, while blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy characterized by the aggressive proliferation of plasmacytoid dendritic cell precursors. This article focuses on the diagnosis and management of BPDCN according to the NCCN Guidelines for AML.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2023)

Add to Collection

Article Hematology

Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors

Yazan Numan et al.

Summary: This research analyzed 113 patients with relapsed/refractory FLT3(mut+) AML who received gilteritinib treatment and found a CRc rate of 48.7%. Among patients who received 7+3 and midostaurin treatment, the CRc rate after gilteritinib treatment was 58% with a median survival of 7.8 months. Patients who achieved CR, especially those with a cMRD negative response, had the longest survival.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Article Hematology

Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Alexander E. Perl et al.

Summary: The follow-up of the ADMIRAL trial after 2 years demonstrates that gilteritinib is a safe and effective treatment option for patients with relapsed/refractory FLT3-mutation-positive AML. Gilteritinib therapy provides superior overall survival and long-term remission compared to salvage chemotherapy, especially when used as post-HSCT maintenance.

BLOOD (2022)

Add to Collection

Article Hematology

Molecular profile of FLT3-mutated relapsed/refractory AML patients in the phase 3 ADMIRAL study of gilteritinib

Catherine C. Smith et al.

Blood Advances (2022)

Add to Collection

Review Hematology

A review of FLT3 inhibitors in acute myeloid leukemia

Jennifer C. Zhao et al.

Summary: FLT3 mutations are the most common genetic aberrations in AML and are associated with poor prognosis. There are several targeted therapies available, such as midostaurin and gilteritinib, but challenges like drug resistance mechanisms and controversies surrounding maintenance therapy remain.

BLOOD REVIEWS (2022)

Add to Collection

Article Oncology

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib

Alexander E. Perl et al.

Summary: Gilteritinib is effective for FLT3-mutated relapsed/refractory AML, even in patients who had prior treatment with sorafenib or midostaurin. However, remission durations are shorter in patients with prior FLT3 TKI exposure.

BLOOD CANCER JOURNAL (2022)

Add to Collection

Article Hematology

Phase 3 Trial of Gilteritinib Plus Azacitidine Vs Azacitidine for Newly Diagnosed FLT3mut+ AML Ineligible for Intensive Chemotherapy

Eunice S. Wang et al.

BLOOD (2022)

Add to Collection

Article Hematology

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Hartmut Doehner et al.

Summary: The 2010 and 2017 editions of the European LeukemiaNet recommendations for AML diagnosis and management are widely recognized. There have been major advances in our understanding of AML, including disease classification updates, improvements in genomic diagnostics, and the development of new therapeutic agents. This update includes a revised genetic risk classification, response criteria, and treatment recommendations.

BLOOD (2022)

Add to Collection

Article Oncology

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia

Naval Daver et al.

Summary: Combining gilteritinib with venetoclax has shown promising results in treating relapsed/refractory FLT3-mutated AML, with high rates of response and molecular remission regardless of prior FLT3 inhibitor therapy.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax

Jan Philipp Bewersdorf et al.

Summary: A multicenter retrospective cohort study found that response rates to FLT3, IDH1, and IDH2 inhibitors after venetoclax-based therapy were low in patients with AML. Patients with RAS pathway mutations did not respond well to targeted agents, and mutations in TP53 and KRAS were associated with shorter overall survival. This suggests the need for novel therapeutic strategies.

LEUKEMIA RESEARCH (2022)

Add to Collection

Article Biophysics

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

Richard T. Maziarz et al.

Summary: The study evaluated the efficacy of adding midostaurin to standard-of-care treatment in preventing relapse following alloHSCT in FLT3-ITD AML patients. Results showed an 18-month RFS rate of 89% in the midostaurin maintenance therapy group compared to 76% in the SOC group. The inhibition of FLT3 phosphorylation to <70% of baseline was associated with improved RFS, indicating potential clinical benefit in some patients.

BONE MARROW TRANSPLANTATION (2021)

Add to Collection

Letter Oncology

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Abhishek Maiti et al.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Oncology

Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors

Ahmad S. Alotaibi et al.

Summary: The study revealed distinct emergent mutations in FLT3-mutated AML patients treated with FLT3 inhibitors, indicating different pathways of secondary resistance. Furthermore, pretreatment RAS/MAPK mutations may be associated with primary resistance in patients.

BLOOD CANCER DISCOVERY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation

Ruiqi Zhu et al.

Summary: Combining FLT3 TKIs with BCL-2 selective inhibitors synergistically reduces cell proliferation and enhances apoptosis, resensitizing FLT3 TKI-resistant cells. Venetoclax mitigates the pro-survival effects of FLT3 TKIs by dissociating BIM from BCL-2 and decreasing BIM expression. This study provides evidence that adding BCL-2 inhibitors enhances the efficacy of FLT3 TKI therapy in FLT3/ITD AML treatment.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection

Article Oncology

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)

Andreas Burchert et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia

Lindsey T. Brinton et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection

Review Hematology

Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation

Serena Chew et al.

THERAPEUTIC ADVANCES IN HEMATOLOGY (2020)

Add to Collection

Article Oncology

Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia

Christine M. McMahon et al.

CANCER DISCOVERY (2019)

Add to Collection

Article Oncology

Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia

Jun Ma et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Review Oncology

Targeting FLT3 mutations in AML: review of current knowledge and evidence

Naval Daver et al.

LEUKEMIA (2019)

Add to Collection

Article Medicine, General & Internal

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

R. M. Stone et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Hematology

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials

PD Kottaridis et al.

BLOOD (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.